1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Veterinary Monoclonal Antibodies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Veterinary Monoclonal Antibodies Market Revenue and Volume, by Animal Type
8.1.1. Dogs (Canine)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Cats (Feline)
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Livestock Animals
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Other Companion Animals
8.1.4.1. Market Revenue and Volume Forecast
9.1. Veterinary Monoclonal Antibodies Market Revenue and Volume, by Product Type
9.1.1. Anti-IL-31 Monoclonal Antibodies
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Anti-NGF Monoclonal Antibodies
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Immune-Modulating mAbs
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Other Targeted mAbs
9.1.4.1. Market Revenue and Volume Forecast
10.1. Veterinary Monoclonal Antibodies Market Revenue and Volume, by Therapy Area
10.1.1. Dermatology (Atopic Dermatitis)
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Pain Management / Osteoarthritis
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Infectious Diseases
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Oncology
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Other Therapeutic Areas
10.1.5.1. Market Revenue and Volume Forecast
11.1. Veterinary Monoclonal Antibodies Market Revenue and Volume, by Route of Administration
11.1.1. Injectable Monoclonal Antibodies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Subcutaneous Formulations
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Other Delivery Methods
11.1.3.1. Market Revenue and Volume Forecast
12.1. Veterinary Monoclonal Antibodies Market Revenue and Volume, by End User
12.1.1. Veterinary Hospitals
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Veterinary Clinics
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Research Institutions
12.1.3.1. Market Revenue and Volume Forecast
12.1.4. Other Animal Healthcare Providers
12.1.4.1. Market Revenue and Volume Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Animal Type
13.1.2. Market Revenue and Volume Forecast, by Product Type
13.1.3. Market Revenue and Volume Forecast, by Therapy Area
13.1.4. Market Revenue and Volume Forecast, by Route of Administration
13.1.5. Market Revenue and Volume Forecast, by End User
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Animal Type
13.1.6.2. Market Revenue and Volume Forecast, by Product Type
13.1.6.3. Market Revenue and Volume Forecast, by Therapy Area
13.1.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.1.6.5. Market Revenue and Volume Forecast, by End User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Animal Type
13.1.7.2. Market Revenue and Volume Forecast, by Product Type
13.1.7.3. Market Revenue and Volume Forecast, by Therapy Area
13.1.7.4. Market Revenue and Volume Forecast, by Route of Administration
13.1.7.5. Market Revenue and Volume Forecast, by End User
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Animal Type
13.2.2. Market Revenue and Volume Forecast, by Product Type
13.2.3. Market Revenue and Volume Forecast, by Therapy Area
13.2.4. Market Revenue and Volume Forecast, by Route of Administration
13.2.5. Market Revenue and Volume Forecast, by End User
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Animal Type
13.2.6.2. Market Revenue and Volume Forecast, by Product Type
13.2.6.3. Market Revenue and Volume Forecast, by Therapy Area
13.2.7. Market Revenue and Volume Forecast, by Route of Administration
13.2.8. Market Revenue and Volume Forecast, by End User
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Animal Type
13.2.9.2. Market Revenue and Volume Forecast, by Product Type
13.2.9.3. Market Revenue and Volume Forecast, by Therapy Area
13.2.10. Market Revenue and Volume Forecast, by Route of Administration
13.2.11. Market Revenue and Volume Forecast, by End User
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Animal Type
13.2.12.2. Market Revenue and Volume Forecast, by Product Type
13.2.12.3. Market Revenue and Volume Forecast, by Therapy Area
13.2.12.4. Market Revenue and Volume Forecast, by Route of Administration
13.2.13. Market Revenue and Volume Forecast, by End User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Animal Type
13.2.14.2. Market Revenue and Volume Forecast, by Product Type
13.2.14.3. Market Revenue and Volume Forecast, by Therapy Area
13.2.14.4. Market Revenue and Volume Forecast, by Route of Administration
13.2.15. Market Revenue and Volume Forecast, by End User
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Animal Type
13.3.2. Market Revenue and Volume Forecast, by Product Type
13.3.3. Market Revenue and Volume Forecast, by Therapy Area
13.3.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.5. Market Revenue and Volume Forecast, by End User
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Animal Type
13.3.6.2. Market Revenue and Volume Forecast, by Product Type
13.3.6.3. Market Revenue and Volume Forecast, by Therapy Area
13.3.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.7. Market Revenue and Volume Forecast, by End User
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Animal Type
13.3.8.2. Market Revenue and Volume Forecast, by Product Type
13.3.8.3. Market Revenue and Volume Forecast, by Therapy Area
13.3.8.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.9. Market Revenue and Volume Forecast, by End User
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Animal Type
13.3.10.2. Market Revenue and Volume Forecast, by Product Type
13.3.10.3. Market Revenue and Volume Forecast, by Therapy Area
13.3.10.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.10.5. Market Revenue and Volume Forecast, by End User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Animal Type
13.3.11.2. Market Revenue and Volume Forecast, by Product Type
13.3.11.3. Market Revenue and Volume Forecast, by Therapy Area
13.3.11.4. Market Revenue and Volume Forecast, by Route of Administration
13.3.11.5. Market Revenue and Volume Forecast, by End User
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Animal Type
13.4.2. Market Revenue and Volume Forecast, by Product Type
13.4.3. Market Revenue and Volume Forecast, by Therapy Area
13.4.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.5. Market Revenue and Volume Forecast, by End User
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Animal Type
13.4.6.2. Market Revenue and Volume Forecast, by Product Type
13.4.6.3. Market Revenue and Volume Forecast, by Therapy Area
13.4.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.7. Market Revenue and Volume Forecast, by End User
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Animal Type
13.4.8.2. Market Revenue and Volume Forecast, by Product Type
13.4.8.3. Market Revenue and Volume Forecast, by Therapy Area
13.4.8.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.9. Market Revenue and Volume Forecast, by End User
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Animal Type
13.4.10.2. Market Revenue and Volume Forecast, by Product Type
13.4.10.3. Market Revenue and Volume Forecast, by Therapy Area
13.4.10.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.10.5. Market Revenue and Volume Forecast, by End User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Animal Type
13.4.11.2. Market Revenue and Volume Forecast, by Product Type
13.4.11.3. Market Revenue and Volume Forecast, by Therapy Area
13.4.11.4. Market Revenue and Volume Forecast, by Route of Administration
13.4.11.5. Market Revenue and Volume Forecast, by End User
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Animal Type
13.5.2. Market Revenue and Volume Forecast, by Product Type
13.5.3. Market Revenue and Volume Forecast, by Therapy Area
13.5.4. Market Revenue and Volume Forecast, by Route of Administration
13.5.5. Market Revenue and Volume Forecast, by End User
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Animal Type
13.5.6.2. Market Revenue and Volume Forecast, by Product Type
13.5.6.3. Market Revenue and Volume Forecast, by Therapy Area
13.5.6.4. Market Revenue and Volume Forecast, by Route of Administration
13.5.7. Market Revenue and Volume Forecast, by End User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Animal Type
13.5.8.2. Market Revenue and Volume Forecast, by Product Type
13.5.8.3. Market Revenue and Volume Forecast, by Therapy Area
13.5.8.4. Market Revenue and Volume Forecast, by Route of Administration
13.5.8.5. Market Revenue and Volume Forecast, by End User
14.1. Zoetis
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Boehringer Ingelheim
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Merck Animal Health
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Elanco Animal Health
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Virbac
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Ceva Santé Animale
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Merial
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Abaxis
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
